This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits.
No takes yet. Share an insight, caveat, or question.
Anna Bock (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: